In a little over two decades, almost 260 million people in the United States are predicted to have overweight or obesity, ...

Several upcoming events could serve as significant catalysts for Skye Bioscience's stock: 1. Interim data from the Phase 2 obesity trial expected in 2Q25 could provide early insights into ...

Amgen (NASDAQ:AMGN) shares fell in late afternoon trading Tuesday after Cantor Fitzgerald argued that a potential loss of bone mineral density could be a safety risk linked to its obesity ...

Several upcoming events could serve as significant catalysts for Skye Bioscience's stock: 1. Interim data from the Phase 2 obesity trial expected in 2Q25 could provide early insights into nimacimab's ...

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

Oct. 30, 2024 — Young people with severe obesity who underwent weight-loss surgery at age 19 or younger continued to see sustained weight loss and resolution of common obesity-related ...

The stock previously shed more than 7% in the prior ... In October, Amgen said that mid-stage trial results for the potentially lucrative obesity medicine would be available in late 2024.

Furthermore, we are excited to advance our obesity programs and start multiple clinical trials ... can be found at via the identifier NCT06565611 Presented a poster titled "Structural Modification ...

In conclusion, JPMorgan's analysis suggests that the upcoming trial data could solidify Novo Nordisk's position in the obesity treatment market. The firm remains confident in the stock's performance ...

GZR18 is an investigational drug and is not approved for use in any country. Gan & Lee Pharmaceuticals does not endorse the use of any unapproved drug or indication. The Phase 2b clinical trial ...